Clinical trials · Texas
Leukemia clinical trials in Texas
We’re tracking 211 recruiting leukemia studies with a site in Texas — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in Texas
- NCT04877522RecruitingPhase 4
Continued asciminib treatment for certain leukemia patients
This trial lets people who already have Philadelphia chromosome–positive (Ph+) leukemia and are benefiting from asciminib (or certain related medicines) continue treatment. It mainly tests whether ongoing care in a follow-on study is safe and workable for participants.
Houston, TexasAges 7–100 - NCT05010564RecruitingPhase 1
TRICAR-ALL CAR-T treatment for tough childhood leukemia
This Phase 1 trial tests a customized CAR-T cell therapy for children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) that keeps coming back or doesn’t respond to treatment. It aims to find a safer and effective way to control leukemia by targeting specific markers on the leukemia cells.
Houston, TexasAges 1–25 - NCT05010772RecruitingPhase 1
Maintenance treatment study for AML in remission
This Phase 1 trial tests whether continuing decitabine alone or with other targeted drugs can help prevent AML from coming back after you reach remission. It’s designed to study safety and how well these maintenance options work for people who are not immediately able to get a stem cell transplant.
Houston, TexasAges 18 years+ - NCT05143996RecruitingPhase 1
First study drug for relapsed AML or MDS
This Phase 1 trial tests CLN-049 in adults whose acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) has come back or did not respond to treatment. The goal is to find out how well the drug can work and how safe it is in people with limited options.
Houston, TexasAges 18 years+ - NCT05183035RecruitingPhase 3
Venetoclax for relapsed childhood AML
This trial studies venetoclax in children and young adults whose acute myeloid leukemia (AML) has come back. It aims to see how well this treatment controls the leukemia after earlier therapies.
Dallas, TexasAges 4 weeks–21 years - NCT05360160RecruitingPhase 1/Phase 2
Oral menin inhibitor plus AML medicines for new or relapsed AML
This trial tests an all-pill (oral) combination treatment—menin inhibitor SNDX-5613 plus decitabine/cedazuridine (ASTX727) and venetoclax—for acute myeloid leukemia (AML). It’s designed for people who are newly diagnosed and can’t get the strongest chemotherapy, or for certain other AML groups who may still benefit.
Houston, TexasAges 12 years+ - NCT05365035RecruitingPhase 2
Phase 2 trial for high-risk blood cancers with timed chemo
This study tests a mix of medicines (cladribine, low-dose cytarabine, and venetoclax) alternated with azacitidine and venetoclax to treat higher-risk CMML or MDS after prior treatment or when standard treatment may not work well. It may help by improving blood counts and controlling the disease.
Houston, TexasAges 18 years+ - NCT05512390RecruitingPhase 1
Test drug ABBV-319 in B-cell blood cancers
This Phase 1 trial studies ABBV-319 given by vein to see what side effects it causes and how the cancer activity changes in certain B-cell blood cancers. It may help people with relapsed or treatment-resistant disease by exploring new treatment options and better understanding how the drug moves through the body.
Dallas, TexasAges 18 years+ - NCT05536349RecruitingPhase 2
Testing three drug combo for untreated CLL or CLL-related cancer
This Phase 2 study tests pirtobrutinib plus venetoclax plus obinutuzumab in people with untreated chronic lymphocytic leukemia (CLL) or CLL-related Richter transformation (RT). The goal is to see if this “triplet” combination works better and is safe enough to control the disease.
Houston, TexasAges 18 years+ - NCT05645718RecruitingPhase 2
Chemo plus targeted antibodies for relapsed childhood B-ALL
This Phase 2 study tests a combination treatment for children, teens, or young adults whose B-cell acute lymphoblastic leukemia (B-ALL) has come back or did not respond to initial therapy. It may help patients who cannot safely receive certain standard medicines like anthracyclines or who cannot tolerate PEG-asparaginase.
Houston, TexasAges 1–25 - NCT05732103RecruitingPhase 1/Phase 2
Testing CTX-712 for AML or high-risk MDS after prior treatment
This early-phase study tests CTX-712, a new cancer treatment, in people whose acute myeloid leukemia (AML) or certain high-risk blood cancers came back or did not respond to prior therapy. It may help shrink the cancer and control the disease by targeting it differently than standard treatments.
Houston, TexasAges 18 years+ - NCT05745285Recruiting
LLS care support program for blood cancer patients
This study looks at whether LLS services and support improve outcomes and the day-to-day experience of care for people with leukemia, lymphoma, myeloma, MDS, or MPN. It’s mainly about matching you to the right support and following your progress for 6 months.
San Antonio, TexasAges 18 years+ - NCT05834244RecruitingPhase 1
New and relapsed AML treatment using azacitidine, venetoclax, and NK cells
This Phase 1 trial tests a combination of azacitidine, venetoclax, and donor NK cells to treat acute myeloid leukemia (AML) or certain AML-like syndromes. It’s designed mainly to find safe dosing and whether this approach can control the leukemia.
Houston, TexasAges 18 years+ - NCT05848687RecruitingPhase 1/Phase 2
Newborns with CD19 leukemia may try a combined infant therapy
This early-phase study is testing a “total therapy” treatment plan for very young babies (diagnosed within the first year of life) with certain types of leukemia that carry the CD19 marker. It may help find safer and more effective treatment for infants with this disease, especially soon after diagnosis.
San Antonio, TexasAges Up to 1 year - NCT06034275RecruitingPhase 1
Study of VIP943 for CD123-positive blood cancers
This trial tests a new drug called VIP943 for people with advanced acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL), or myelodysplastic syndrome (MDS) whose cancer cells have a marker called CD123. It is for those who have tried all other treatments or cannot receive them.
Houston, TexasAges 18 years+ - NCT06071624RecruitingPhase 1
CAR T-cell therapy for CMML that has come back
This trial tests a new type of immune cell therapy (CAR T-cells) that targets CD4 on CMML cells. It is for people whose CMML has come back or not responded to standard treatment.
Houston, TexasAges 18 years+ - NCT06088888RecruitingPhase 1
TGRX-678 for CML that hasn't responded to other treatments
This study tests a new daily pill called TGRX-678 for people with chronic-phase CML who have not responded well to or cannot tolerate other CML treatments. It aims to see if the drug is safe and if it can help control the leukemia.
Houston, TexasAges 18 years+ - NCT06146257RecruitingPhase 1
Study of GLB-001 for Relapsed or Refractory AML or High-Risk MDS
This trial tests an oral investigational drug (GLB-001) for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that has returned or hasn't responded to other treatments. The goal is to see if it's safe and effective for those who have run out of standard options.
Houston, TexasAges 18 years+ - NCT06173518RecruitingPhase 1
CAR T-cell therapy for children with B-cell leukemia or lymphoma
This trial tests a CAR T-cell therapy that targets CD19 on cancer cells. It is for children whose B-cell acute lymphoblastic leukemia or aggressive B-cell non-Hodgkin lymphoma has come back or not responded to other treatments.
San Antonio, TexasAges birth–18 years - NCT06191978RecruitingPhase 1
Testing venetoclax with decitabine/cedazuridine for pediatric AML
This trial tests a combination of two oral drugs (venetoclax and decitabine/cedazuridine) for children and teens whose acute myeloid leukemia (AML) has returned or not improved after prior treatment. The goal is to find a safe dose and see if the drugs can help shrink or control the leukemia.
Houston, TexasAges 2–18 - NCT06197672RecruitingPhase 1
CAR T cells for CD4-positive AML before stem cell transplant
This trial tests a new type of immunotherapy (CAR T cells) designed to target and kill leukemia cells that have a specific marker (CD4). The goal is to help people with acute myeloid leukemia (AML) that has not responded to standard treatments get ready for a stem cell transplant.
Houston, TexasAges 12 years+ - NCT06229912RecruitingPhase 2
Revumenib for leukemia with HOX gene changes
This trial tests an oral drug called revumenib (a menin inhibitor) for patients with acute leukemia that has returned or not responded to treatment, and whose leukemia has a specific HOX gene change. Revumenib aims to stop cancer growth by blocking a protein that helps leukemia cells survive.
Houston, TexasAges 12 years+ - NCT06236724RecruitingPhase 2
Asciminib for newly diagnosed chronic myeloid leukemia
This study tests a targeted pill called asciminib for people newly diagnosed with chronic-phase CML. It aims to see if this drug is safe and effective as an early treatment option.
Houston, TexasAges 18 years+ - NCT06285890RecruitingPhase 1
HC-7366 study for relapsed or refractory AML
This trial tests a new drug called HC-7366 for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. It aims to see if this drug is safe and helpful when standard options are no longer working.
Houston, TexasAges 18 years+
Leukemia trials by city in Texas
Where these studies are running in Texas
Institutions with a site for the recruiting leukemia studies listed above.
- The University of Texas MD Anderson Cancer Center · 19 studies
- Texas Children's Hospital · 2 studies
- University of Texas Health Science Center at San Antonio · 2 studies
- Baylor Charles A. Sammons Cancer Center
- Local Institution
- Methodist Healthcare System of San Antonio
- Texas Oncology
- University of Texas Southwestern Medical Center
What taking part in a leukemia study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Leukemia trials in other states
Common questions
- Are there leukemia clinical trials in Texas?
- Yes. We're currently tracking 211 recruiting leukemia studies with a site in Texas, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a leukemia study in Texas?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Texas to take part?
- Not necessarily. These studies have a site in Texas, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a leukemia trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New leukemia studies open in Texas regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.